%0 Journal Article
%T Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions
%A Marzan KA
%J Adolescent Health, Medicine and Therapeutics
%D 2012
%I 
%R http://dx.doi.org/10.2147/AHMT.S22607
%X le of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions Review (1710) Total Article Views Authors: Marzan KA Published Date June 2012 Volume 2012:3 Pages 85 - 93 DOI: http://dx.doi.org/10.2147/AHMT.S22607 Received: 01 February 2012 Accepted: 17 April 2012 Published: 20 June 2012 Katherine Anne B Marzan Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, USA Abstract: Treatment of children and adolescents with juvenile idiopathic arthritis and other pediatric rheumatic diseases has evolved. Where once there was only a limited arsenal of medications, with significant side effects and inadequate efficacy, today, with an increased understanding of the pathogenesis of these diseases, there is a wider variety of more targeted and effective treatments. TNF-¦Á is a cytokine involved in a number of inflammatory pathways in pediatric rheumatic diseases. The emergence of biologic modifiers that target TNF-¦Á has been pivotal in providing the ability to deliver early and aggressive treatment. Adalimumab, a recombinant monoclonal antibody to TNF-¦Á, is an important therapeutic option, which affords children and adolescents with chronic illnesses an improved quality of life.
%K adalimumab
%K juvenile idiopathic arthritis
%K TNF-¦Á
%K pediatric
%K rheumatic diseases
%K treatment
%U https://www.dovepress.com/role-of-adalimumab-in-the-management-of-children-and-adolescents-with--peer-reviewed-article-AHMT